<DOC>
	<DOC>NCT00653172</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy, safety and tolerance of 2 different dose levels of oral NXL103 with oral comparator in the treatment of community acquired pneumonia in adults</brief_summary>
	<brief_title>Comparative Study of NXL103 Versus Comparator in Adults With Community Acquired Pneumonia</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Streptogramin A</mesh_term>
	<criteria>Community acquired pneumonia severe CAP respiratory infections attributed to sources other than community acquired bacterial infection concomitant pulmonary disease history of hypersensitivity to study medication, macrolide or beta lactam antibiotics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>CAP</keyword>
	<keyword>community acquired pneumonia</keyword>
</DOC>